Galapagos : Une accélération forte des frais de R&D
>Une forte accélération des frais de R&D - Galapagos a publié hier ses résultats du T3 après la fermeture du marché US. Les revenus s’élèvent à 60 M€ vs 70 M€ att. Ces revenus viennent essentiellement de la reconnaissance de son accord portée sur 10 ans avec Gilead. Au niveau des couts, les Opex accélèrent très fortement sur les 9premiers mois de l’année.L’activité de R&D se développe logiquement suite aux avancées des programmes cliniques, mais les coûts s...Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.